Brittany Lovely - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Brittany Lovely's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Brittany Lovely
Verified
Managing Editor, Professional Content, American Cancer Society
New Jersey, Bordentown
Beats
Astronomy and stargazing
Content
By Hannah Clarke, Jason Broderick Verified, Brittany Lovely| Urology Times Verified The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of erdafitinib (Balversa) as a monotherapy in the treatment of adult patients with unresectable or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations who have received at least 1 prior line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.1 “FGFR alterations are...
By Jason Broderick Verified, Brittany Lovely| Urology Times Verified The FDA has granted a full approval to erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least 1 line of prior systemic therapy. It is not recommended for patients who, despite being eligible, have not received treatment with PD-1/PD-L1 checkpoint inhibitors.
By Hannah Clarke, Jason Broderick Verified, Brittany Lovely| Urology Times Verified The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of erdafitinib (Balversa) as a monotherapy in the treatment of adult patients with unresectable or metastatic urothelial carcinoma harboring susceptible FGFR3 genetic alterations who have received at least 1 prior line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.1 “FGFR alterations are...
Company Info
NeurologyLive is a multimedia platform focused on delivering the latest news and insights in the field of neurology. It serves as a valuable resource for healthcare professionals, particularly those treating neurological diseases. The platform offers a combination of print and digital media, ensuring that busy clinicians stay informed about significant developments in neurology. The services provided by NeurologyLive include breaking news on drug approvals, clinical trials, and emerging trends in neurological care. It features expert interviews with leading neurologists, offering insights into the latest research and clinical practices. The use of multimedia content makes the information accessible and engaging for its audience. NeurologyLive targets healthcare professionals such as neurologists, clinicians, and researchers. It has established strategic partnerships with organizations like the Consortium of Multiple Sclerosis Centers, enhancing its credibility and reach within the neurology community. Its comprehensive coverage and expert engagement position NeurologyLive as a trusted source for the latest developments in the field.
Cranbury, United States
+1 609-716-7777
Founded: 2018